Target intelligence / Profile preview

Epstein-Barr virus latent membrane protein 2 peptide-human leukocyte antigen complex (EBV LMP2 peptide-HLA complex)

Target
EBV LMP2 peptide-HLA complex
Molecular classification
Peptide-MHC complex, Other
01

Overview

The Epstein-Barr virus latent membrane protein 2 (LMP2) peptide-human leukocyte antigen (HLA) complex is a major histocompatibility complex (MHC) class I-restricted target presented on the surface of cells infected with Epstein-Barr virus (EBV). LMP2 is a viral latency II protein expressed in several EBV-associated malignancies, including nasopharyngeal carcinoma (NPC), Hodgkin lymphoma, Burkitt lymphoma, and post-transplant lymphoproliferative disorders (PTLD). Because LMP2 is an intracellular protein, its peptide fragments (such as the immunodominant CLGGLLTMV epitope) are processed and presented on the cell surface in complex with HLA class I molecules, most commonly HLA-A*02:01, HLA-A*24:02, or HLA-A*11:01. This peptide-HLA complex serves as a highly specific target for cellular immunotherapies, including T-cell receptor-engineered T-cell (TCR-T) therapies, chimeric antigen receptor (CAR) T-cell therapies utilizing TCR-mimic (TCRm) antibodies, and bispecific T-cell engagers. Therapeutic candidates like YT-E001 and various TCRm bispecific antibodies (e.g., E38) are designed to recognize this complex to selectively eliminate EBV-positive tumor cells while sparing healthy tissues. However, challenges such as HLA downregulation, epitope mutations, and potential cross-reactivity with self-peptides present significant hurdles in clinical development.

Other names
EBV LMP2 peptide-HLA complexEpstein-Barr virus latent membrane protein 2 peptide-HLA complexLMP2 peptide-MHC complexEBV LMP2 peptide-MHC complexLMP2/HLA complexLMP2/HLA-A*02:01 complexLMP2/HLA-A2 complexCLGGLLTMV/HLA-A*02:01 complexLMP2 peptide-HLA complex
02

Mechanism of action

Drugs targeting this complex act by mimicking T-cell receptors (TCRs) or utilizing engineered TCRs to redirect the host immune system, specifically cytotoxic T lymphocytes, to recognize and destroy cells presenting the viral LMP2 peptide on their HLA molecules.

03

Biological functions

Antigen presentationImmune responseT-cell activation
04

Disease associations

CancerInfectionOther
05

Safety considerations

Off-target toxicity due to cross-reactivity with self-peptidesOn-target, off-tumor toxicityCytokine release syndrome (CRS)Immune effector cell-associated neurotoxicity syndrome (ICANS)Tumor immune escape via HLA downregulation or lossEpitope mutations leading to viral escape
06

Interacting drugs

2 more in the full profile.

07

Biomarkers

HLA-A*02:01 expressionHLA-A*24:02 expressionHLA-A*11:01 expressionEBV DNA copy numberLMP2 expression

Beyond the preview

Go deeper on Epstein-Barr virus latent membrane protein 2 peptide-human leukocyte antigen complex (EBV LMP2 peptide-HLA complex).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epstein-Barr virus latent membrane protein 2 peptide-human leukocyte antigen complex (EBV LMP2 peptide-HLA complex).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call